Ultrafiltration for Circular RNA Purification: Advancing RNA Therapeutics

Study Background and Research Question

The emergence of messenger RNA (mRNA) vaccines, particularly in response to COVID-19, has highlighted the transformative potential of RNA-based therapeutics. However, traditional linear mRNA molecules are inherently unstable in vivo, with their free ends subject to rapid exonuclease-mediated degradation. This instability limits the duration of protein expression and necessitates complex modifications—such as nucleoside analogs and synthetic 5’ caps—to prolong activity, often with only moderate success. Circular RNAs (circRNAs), lacking free ends, offer superior stability, reduced immunogenicity, and sustained protein production. Yet, a major technical bottleneck has been the inability to efficiently purify circRNA from reaction mixtures that also contain linear precursor and nicked RNA byproducts. Guillen-Cuevas et al. sought to address this gap by evaluating whether ultrafiltration—a scalable, membrane-based separation technology—could selectively enrich for protein-coding circRNA, thereby enabling more robust and reproducible therapeutic RNA applications.

Key Innovation from the Reference Study

The central advancement in the study by Guillen-Cuevas et al. is the systematic application of ultrafiltration for circRNA purification following in vitro transcription (IVT) and self-splicing. Unlike existing chromatographic methods, ultrafiltration leverages differences in molecular size and conformation to separate circular, linear, and nicked RNA species using polyethersulfone membranes with defined molecular weight cutoffs. The authors demonstrated that this approach yields circRNA of higher purity and comparable or improved yield relative to industry-standard size-exclusion high-performance liquid chromatography (SE-HPLC), thus overcoming a key hurdle in the scalable production of therapeutic circRNAs.

Methods and Experimental Design Insights

The study focused on protein-encoding circRNA generated via IVT and self-splicing of engineered linear precursor RNA (preRNA) templates. Ultrafiltration experiments utilized polyethersulfone membranes with molecular weight cutoffs ranging from 30 to 300 kDa. The authors quantified the separation performance by measuring sieving coefficients for three RNA species: circRNA, linear preRNA, and nicked conformers. Performance was systematically assessed across a range of permeate fluxes to identify optimal operating conditions that maximize circRNA retention while minimizing contamination by linear or nicked forms. Additionally, the team estimated critical flux values for each RNA species and established a set of practical parameters for achieving robust purification.

Protocol Parameters

• Membrane selection: Polyethersulfone ultrafiltration membranes with 100–300 kDa molecular weight cutoff are optimal for separating circular from linear RNA species.
• Permeate flux: Operating at fluxes below the critical flux of the target circRNA (as experimentally determined) preserves product integrity and selectivity.
• IVT/self-splicing conditions: Ensure high-efficiency circularization by optimizing magnesium concentration and reaction time, as incomplete splicing increases linear RNA contamination.
• Product analysis: Use gel electrophoresis or HPLC to quantify purity and yield of circRNA following filtration.
• Yield and purity: Under optimized conditions, expect circRNA purity of ~86% with yields above 50% as demonstrated in the reference study.

Core Findings and Why They Matter

Guillen-Cuevas et al. report that ultrafiltration can achieve up to 86% circRNA purity with more than 50% recovery, substantially outperforming SE-HPLC, which produced only 41% purity and 45% yield under comparable conditions. This finding is significant for several reasons:

• Enhanced therapeutic potential: Higher-purity circRNA reduces immunogenic contaminants, which is critical for in vivo applications and therapeutic gene expression.
• Scalability: Ultrafiltration is already a mainstay in bioprocessing, suggesting straightforward translation from research to manufacturing scale.
• Process simplicity: The method requires fewer steps and less specialized equipment than chromatographic methods, reducing cost and technical barriers for adoption.

These advances may accelerate the deployment of stable RNA therapeutics and vaccines, especially where long-term protein expression and immune evasion are essential.

Comparison with Existing Internal Articles

While the core focus of Guillen-Cuevas et al. is on RNA purification, parallels exist with best practices in microbiology and molecular biology workflows, particularly concerning the use of selection antibiotics. For example, internal discussions of Kanamycin Sulfate highlight its role as a water-soluble antibiotic critical for selecting genetically engineered cells and studying antibiotic resistance mechanisms. Similarly, other internal resources emphasize the importance of high-purity reagents in ensuring experimental reliability in microbiology antibiotic studies. Both contexts underscore the necessity of robust, scalable purification techniques—whether for nucleic acids or antibiotics—to achieve reproducible results and enable downstream research or therapeutic applications. Just as ultrafiltration improves circRNA purity, validated antibiotics like Kanamycin Sulfate (noted for its high water solubility and protein synthesis inhibition) are essential for cell culture selection and anti-infection research workflows, demonstrating a shared emphasis on process optimization and quality control.

Limitations and Transferability

Despite the clear advantages, ultrafiltration for circRNA purification is not without limitations. The study was conducted at the research scale; while ultrafiltration is scalable, parameters such as membrane fouling, long-term process stability, and effects of feed composition variability were not explored in depth. Additionally, the method's efficiency may depend on the size and secondary structure of the target circRNA, necessitating further optimization for different constructs. Transferability to industrial-scale manufacturing will require validation under cGMP conditions and with clinical-grade materials. Importantly, the method does not inherently address the removal of very small RNA fragments or non-nucleic acid contaminants, which may still require supplementary purification steps depending on the intended application.

Research Support Resources

For researchers seeking to implement robust RNA purification and cell selection workflows, the choice of reagents is critical. High-purity, water-soluble antibiotics such as Kanamycin Sulfate (SKU A2516) are widely utilized in both microbiology and molecular biology to enable precise antibiotic resistance selection and to support studies of bacterial protein synthesis inhibition. APExBIO offers Kanamycin Sulfate as a solid, water-soluble aminoglycoside antibiotic, suitable for integration into advanced microbial and molecular workflows. As with nucleic acid purification, careful reagent selection and protocol optimization are key to achieving reliable, reproducible results in anti-infection research and related applications.